These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20676118)

  • 1. Non-peptidic glucose-like peptide-1 receptor agonists: aftermath of a serendipitous discovery.
    Wang MW; Liu Q; Zhou CH
    Acta Pharmacol Sin; 2010 Sep; 31(9):1026-30. PubMed ID: 20676118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A continued saga of Boc5, the first non-peptidic glucagon-like peptide-1 receptor agonist with in vivo activities.
    He M; Guan N; Gao WW; Liu Q; Wu XY; Ma DW; Zhong DF; Ge GB; Li C; Chen XY; Yang L; Liao JY; Wang MW
    Acta Pharmacol Sin; 2012 Feb; 33(2):148-54. PubMed ID: 22301855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Landmark studies on the glucagon subfamily of GPCRs: from small molecule modulators to a crystal structure.
    Yang DH; Zhou CH; Liu Q; Wang MW
    Acta Pharmacol Sin; 2015 Sep; 36(9):1033-42. PubMed ID: 26279155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice.
    Chen D; Liao J; Li N; Zhou C; Liu Q; Wang G; Zhang R; Zhang S; Lin L; Chen K; Xie X; Nan F; Young AA; Wang MW
    Proc Natl Acad Sci U S A; 2007 Jan; 104(3):943-8. PubMed ID: 17213311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.
    Yamagishi S; Matsui T
    Curr Pharm Des; 2011 Dec; 17(38):4379-85. PubMed ID: 22204436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule drug discovery at the glucagon-like peptide-1 receptor.
    Willard FS; Bueno AB; Sloop KW
    Exp Diabetes Res; 2012; 2012():709893. PubMed ID: 22611375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide 1 (GLP-1) and metabolic diseases.
    Rotella CM; Pala L; Mannucci E
    J Endocrinol Invest; 2005 Sep; 28(8):746-58. PubMed ID: 16277173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors.
    Darbalaei S; Yuliantie E; Dai A; Chang R; Zhao P; Yang D; Wang MW; Sexton PM; Wootten D
    Biochem Pharmacol; 2020 Oct; 180():114150. PubMed ID: 32682761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide: can it make a difference in the treatment of type 2 diabetes?
    Unger J
    Int J Clin Pract Suppl; 2010 Oct; (167):1-3. PubMed ID: 20949698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no.
    Madsbad S
    Eur J Intern Med; 2012 Mar; 23(2):132-6. PubMed ID: 22284242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond glycemic control: cardiovascular effects of incretin-based therapies.
    Angeli FS; Shannon RP
    Front Horm Res; 2014; 43():144-57. PubMed ID: 24943305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Potential of pharmacological modulation of level and activity incretins on diabetes mellitus type 2].
    Spasov AA; Chepljaeva NI
    Biomed Khim; 2015; 61(4):488-96. PubMed ID: 26350740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.